OFLOXACIN

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H20FN3O4
Molecular Weight	361.3675
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4

InChI

InChIKey=GSDSWSVVBLHKDQ-UHFFFAOYSA-N

InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1723377
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/2688325 https://www.ncbi.nlm.nih.gov/pubmed/2688325

Ofloxacin is one of a new generation of fluorinated quinolones structurally related to nalidixic acid, primary mechanism of action is inhibition of bacterial DNA gyrase. It is an orally administered broad spectrum antibacterial drug active against most Gram-negative bacteria, many Gram-positive bacteria and some anaerobes. Clinical trials to date have demonstrated the efficacy of ofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, and sexually transmitted diseases. Adverse effects to ofloxacin are usually mild and include gastrointestinal, central nervous system, and hypersensitivity reactions. Also available in solution for treatment of otic and ophthalmic bacterial infections.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial DNA gyrase 66 Target ID: CHEMBL2311224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3032098	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Bacterial infections 234 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1D19A6DB-6DA5-E7DE-F929-2D18BDFA2CF5	Curative	Approved 8429	OFLOXACIN, TABLET; ORAL Approved Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets and other antibacterial drugs, ofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae or Streptococcus pneumoniae. Community-acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, uncomplicated urethral and cervical gonorrhea due to Neisseria gonorrhoeae. (See WARNINGS.) Nongonococcal urethritis and cervicitis due to Chlamydia trachomatis. (See WARNINGS.) Mixed Infections of the urethra and cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae. (See WARNINGS.) Acute pelvic inflammatory disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae. (See WARNINGS.) NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa . Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin. Therapy with ofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. Launch Date 1.13944324E12
Otitis due to bacterial infections 2 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db221b1-32f3-f6ca-e404-71f56a860d08	Curative	Approved 8429	OFLOXACIN, SOLUTION/DROPS; OTIC Approved Use Ofloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa, and Staphylococcus aureus. Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus,and Streptococcus pneumoniae. Launch Date 1.19085125E12
Bacterial conjunctivitis 34 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe564e33-8f5d-4b57-87a9-7afae02eaf97	Curative	Approved 8429	OFLOXACIN, SOLUTION/DROPS; OPHTHALMIC Approved Use Ofloxacin ophthalmic solution, USP is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS due to: Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumonia); Gram-negative bacteria (Enterobacter cloacae, Haemophilus influenza, Proteus mirabilis, Pseudomonas aeruginosa) CORNEAL ULCERS due to: Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumonia); Gram-negative bacteria (Pseudomonas aeruginosa, Serratia marcascens), Anaerobic species (Propionibacterium acnes) Launch Date 1.36710717E12
Corneal ulcer due to bacterial infections 2 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe564e33-8f5d-4b57-87a9-7afae02eaf97	Curative	Approved 8429	OFLOXACIN, SOLUTION/DROPS; OPHTHALMIC Approved Use Ofloxacin ophthalmic solution, USP is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS due to: Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumonia); Gram-negative bacteria (Enterobacter cloacae, Haemophilus influenza, Proteus mirabilis, Pseudomonas aeruginosa) CORNEAL ULCERS due to: Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumonia); Gram-negative bacteria (Pseudomonas aeruginosa, Serratia marcascens), Anaerobic species (Propionibacterium acnes) Launch Date 1.36710717E12

C_max

Value	Dose	Analyte	Population
1.5 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	OFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	OFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.9 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	OFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.6 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
41.2 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
43.5 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	400 mg 1 times / day steady-state, intravenous dose: 400 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	OFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
14.1 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	OFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
21.2 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	OFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
31.4 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	OFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
61 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	OFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
22.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		OFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
68% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019735s059lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		OFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/	unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/	Other AEs: Traumatic injury, Headache... Other AEs: Traumatic injury (grade 1, 1 patient) Headache (grade 1, 1 patient) Insomnia (grade 2, 2 patients) Malaise and fatigue (grade 1, 1 patient) Nausea (grade 1, 2 patients) Vomiting (grade 1, 4 patients) Reaction skin (grade 1, 1 patient) Pruritus (grade 1, 4 patients) ALT (grade 1, 4 patients) ALT (grade 2, 1patients) Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/
3 g single, intravenous Overdose Dose: 3 g Route: intravenous Route: single Dose: 3 g Sources: https://pubmed.ncbi.nlm.nih.gov/1929271/	unhealthy, 26 years n = 1 Health Status: unhealthy Condition: acute left-upper-lobe pneumonia, asthma Age Group: 26 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1929271/	Disc. AE: CNS disorder (NOS)... AEs leading to discontinuation/dose reduction: CNS disorder (NOS) (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/1929271/
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Co-administed with:: venlafaxine(75 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/15197723/	unhealthy, 43 years n = 1 Health Status: unhealthy Condition: upper respiratory tract infection Age Group: 43 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15197723/	Disc. AE: Orofacial dyskinesia... AEs leading to discontinuation/dose reduction: Orofacial dyskinesia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15197723/
400 mg 1 times / day steady, oral (max) Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10344402/	unhealthy, 81 years n = 1 Health Status: unhealthy Condition: urinary infections Age Group: 81 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10344402/	Other AEs: Psychiatric symptom NOS... Other AEs: Psychiatric symptom NOS (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/10344402/
300 mg 2 times / day steady, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: steady Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3466701/	healthy, adult n = 12 Health Status: healthy Age Group: adult Sex: M Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/3466701/	Sources: https://pubmed.ncbi.nlm.nih.gov/3466701/
400 mg single, oral Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8213104/	healthy, adult n = 525 Health Status: healthy Condition: induced first-trimester abortions Age Group: adult Sex: F Population Size: 525 Sources: https://pubmed.ncbi.nlm.nih.gov/8213104/	Sources: https://pubmed.ncbi.nlm.nih.gov/8213104/

AEs

AE	Significance	Dose	Population
Headache	grade 1, 1 patient	20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/	unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/
Malaise and fatigue	grade 1, 1 patient	20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/	unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/
Reaction skin	grade 1, 1 patient	20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/	unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/
Traumatic injury	grade 1, 1 patient	20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/	unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/
Nausea	grade 1, 2 patients	20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/	unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/
ALT	grade 1, 4 patients	20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/	unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/
Pruritus	grade 1, 4 patients	20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/	unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/
Vomiting	grade 1, 4 patients	20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/	unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/
ALT	grade 2, 1patients	20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/	unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/
Insomnia	grade 2, 2 patients	20 mg/kg 1 times / day steady, oral (max) Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/	unhealthy, 0 - 15 years n = 55 Health Status: unhealthy Condition: multidrug-resistant tuberculosis Age Group: 0 - 15 years Sex: M+F Population Size: 55 Sources: https://pubmed.ncbi.nlm.nih.gov/26195507/
CNS disorder (NOS)	1 patient Disc. AE	3 g single, intravenous Overdose Dose: 3 g Route: intravenous Route: single Dose: 3 g Sources: https://pubmed.ncbi.nlm.nih.gov/1929271/	unhealthy, 26 years n = 1 Health Status: unhealthy Condition: acute left-upper-lobe pneumonia, asthma Age Group: 26 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1929271/
Orofacial dyskinesia	1 patient Disc. AE	400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Co-administed with:: venlafaxine(75 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/15197723/	unhealthy, 43 years n = 1 Health Status: unhealthy Condition: upper respiratory tract infection Age Group: 43 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/15197723/
Psychiatric symptom NOS	1 patient	400 mg 1 times / day steady, oral (max) Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10344402/	unhealthy, 81 years n = 1 Health Status: unhealthy Condition: urinary infections Age Group: 81 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/10344402/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 788 OATP1B3 706 OATP2B1 123 OAT3 642 P-gp 1461	BCRP 561 MRP1 107 BSEP 52

Drug as perpetrator

Target	Modality	Activity
OAT3 644	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/18381565/	no
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	no
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	no
OATP2B1 126	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	no
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15543082/	no

Drug as victim

Target	Modality	Activity
BCRP 561	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/16434544/ \| https://pubmed.ncbi.nlm.nih.gov/17639028/	yes
BSEP 52	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/24014644/	yes
MRP1 107	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/10817732/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/11125032/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7731	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7731
ChemicalBook	CB7103599	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7103599
MolPort	MolPort-000-422-241	https://www.molport.com/shop/molecule-link/MolPort-000-422-241
MolPort	MolPort-000-758-642	https://www.molport.com/shop/molecule-link/MolPort-000-758-642
Selleck Chemicals	Ofloxacin(Floxin)	http://www.selleckchem.com/products/Ofloxacin(Floxin).html
eMolecules	31780819	https://www.emolecules.com/cgi-bin/more?vid=31780819
eMolecules	498886	https://www.emolecules.com/cgi-bin/more?vid=498886

PubMed

Title	Date	PubMed
A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.	2001	11347723
Epidemiological analysis of Salmonella enterica serotype typhimurium from Hong Kong by ribotyping and pulsed-field gel electrophoresis.	2001	11345219
The concentration of three anti-seizure medications in hair: the effects of hair color, controlling for dose and age.	2001	11339881
Antibiotic susceptibility, serum response and surface properties of Klebsiella species.	2001	11297012
Bacillus circulans endophthalmitis.	2001 Apr	11341454
On-column amperometric detection of ofloxacin and pasiniazid in urine by capillary electrophoresis with an improved fractured joint and small detection cell.	2001 Apr	11340975
Endocarditis due to Salmonella.	2001 Apr	11332911
Antibiotic use and development of resistance in blood culture isolates: 8 years of experience from a cancer referral center.	2001 Apr	11330359
In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.	2001 Apr	11322420
[Injectable quinolones].	2001 Apr	11305008
Plasma and BAL fluid concentrations of antimicrobial peptides in patients with Mycobacterium avium-intracellulare infection.	2001 Apr	11296180
Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.	2001 Apr	11296178
Oral fluoroquinolone therapy results in drug adsorption on ureteral stents and prevention of biofilm formation.	2001 Apr	11295415
Comparative efficacy of new investigational agents against Helicobacter pylori.	2001 Apr	11284777
Urothelial mucosal concentration of levofloxacin administered before transurethral resection: Is the mucosal concentration predictable?	2001 Apr	11260349
[Use of levofloxacine in primary care for outbreaks in COPD].	2001 Apr 15	11334579
Stereoselective determination of ofloxacin and its metabolites in human urine by capillary electrophoresis using laser-induced fluorescence detection.	2001 Apr 15	11318412
A whole blood bactericidal assay for tuberculosis.	2001 Apr 15	11262217
Validation of an analytical procedure for the determination of the fluoroquinolone ofloxacin in chicken tissues.	2001 Apr 25	11339274
Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.	2001 Apr 27	11322768
[Recurrent abscesses in a renal transplant recipient].	2001 Feb	11333572
Successful steroid therapy for cefdinir-induced acute tubulointerstitial nephritis with progressive renal failure.	2001 Feb	11300142
Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells.	2001 Jan	11349764
[Levofloxacin adverse effects, data from clinical trials and pharmacovigilance].	2001 Jan-Feb	11322015
Effects of fluoroquinolones on the locomotor activity in rats.	2001 Mar	11357519
Clinical, histopathological and bacteriological investigations in two cases of relapse following ROM treatment.	2001 Mar	11355524
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.	2001 Mar	11337189
Intrapulmonary pharmacokinetics of ofloxacin in drug-resistant tuberculosis.	2001 Mar	11326828
Antidepressant, anxiogenic, and antinociceptive properties of levofloxacin in rats and mice.	2001 Mar	11325396
Treatment of tularemia with levofloxacin.	2001 Mar	11318818
Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.	2001 Mar	11318077
Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea: a randomized, double-blind, multicenter trial.	2001 Mar	11289194
In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.	2001 Mar	11282270
Analysis of fluoroquinolone-mediated photosensitization of 2'-deoxyguanosine, calf thymus and cellular DNA: determination of type-I, type-II and triplet-triplet energy transfer mechanism contribution.	2001 Mar	11281018
[A case of suspected drug-induced ocular pemphigoid].	2001 Mar	11280879
Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.	2001 Mar 12	11266165
Gel-forming erodible inserts for ocular controlled delivery of ofloxacin.	2001 Mar 14	11250096
What have we learned from pharmacokinetic and pharmacodynamic theories?	2001 Mar 15	11249828
Clinical inquiries. What are the most effective treatments for bacterial vaginosis in nonpregnant women?	2001 May	11350701
Predictors of patient response to antibiotic therapy for the chronic prostatitis/chronic pelvic pain syndrome: a prospective multicenter clinical trial.	2001 May	11342913
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.	2001 May	11337224
Antibiotic selective pressure and development of bacterial resistance.	2001 May	11337221
In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens.	2001 May	11333340
Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery.	2001 May	11328803
Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model.	2001 May	11328772
An HPLC assay and a microbiological assay to determine levofloxacin in soft tissue, bone, bile and serum.	2001 May	11275428
Zenker's diverticulum associated with multilevel cervical osteomyelitis.	2001 May 1	11337636
Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates.	2001 May 15	11317266
Methicillin-resistant staphylococci and ofloxacin-resistant bacteria from clinically healthy conjunctivas.	2001 May-Jun	11340403
Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.	2001 Spring	11310803

Patents

Sample Use Guides

In Vivo Use Guide

OFLOXACIN TABLETS: the usual dose of ofloxacin tablets is 200 mg to 400 mg orally every 12 h. Ofloxacin Otic Solution 0.3% for otic use. Otitis Externa: Five drops (0.25 mL, 0.75 mg ofloxacin) instilled into the affected ear once daily for seven days (from 6 months to 13 years old patients). Ten drops (0.5 mL, 1.5 mg ofloxacin) instilled into the affected ear once daily for seven days (for patients 13 years and older). Acute Otitis Media in Pediatric Patients with Tympanostomy Tubes: Five drops (0.25 mL, 0.75 mg ofloxacin) instilled into the affected ear twice daily for ten days. Chronic Suppurative Otitis Media with Perforated Tympanic Membranes: Ten drops (0.5 mL, 1.5 mg ofloxacin) instilled into the affected ear twice daily for fourteen days. Ofloxacin solution 0.3% for topical ophthalmic use. Bacterial conjunctivitis: Days 1 and 2 - Instill one to two drops every two to four hours in the affected eye(s); Days 3 through 7 - Instill one to two drops four times daily. Bacterial corneal ulcer: Days 1 and 2 - Instill one to two drops into the affected eye every 30 minutes, while awake. Awaken at approximately four and six hours after retiring and instill one to two drops; Days 3 through 7 to 9 - Instill one to two drops hourly, while awake; Days 7 to 9 through treatment completion - Instill one to two drops, four times daily.

Route of Administration: Other

In Vitro Use Guide

antibacterial activity of ofloxacin depends on strain: Enterobacteriaceae (MIC less than or equal to 0.12 mg/l), Vibrio cholerae (MIC less than or equal to 0.015 mg/l), V. parahaemolyticus (MIC less than or equal to 0.12 mg/l) Aeromonas hydrophila (MIC less than or equal to 0.03 mg/l), Staphylococcus spp. (MIC less than or equal to 1mg/l), beta-haemolytic Streptococcus spp. (MIC less than or equal to 2 mg/l), Corynebacterium diphtheriae (MIC less than or equal to 1 mg/l) and Cory. jeikeium (MIC less than or equal to 2 mg/l), alpha- and non-haemolytic Streptococcus spp., Str. pneumoniae and Listeria monocytogenes (MIC less than or equal to 4 mg/l for all species) and Str. faecalis (MIC less than or equal to 8 mg/l), Clostridium perfringens (MIC less than or equal to 1 mg/l), Cl. difficile (MIC less than or equal to 16 mg/l), Chlamydia trachomatis SA2f (MIC less than or equal to 0.5 mg/l).

Name

Type

Language

OFLOXACIN

Official Name

English

NSC-758178

Code

English

OFLOXACIN [EP MONOGRAPH]

Common Name

English

HOE-280

Code

English

FLOXIN

Brand Name

English

9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-7H-PYRIDO(1,2,3-DE)(1,4)BENZOXAZINE-6-CARBOXYLIC ACID, DL-

Common Name

English

OFLOXACIN [MART.]

Common Name

English

7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-, (±)-

Common Name

English

Ofloxacin [WHO-DD]

Common Name

English

OFLOXACIN [ORANGE BOOK]

Common Name

English

OFLOXACIN [JAN]

Common Name

English

J01MA01

Code

English

OFLOXACIN [VANDF]

Common Name

English

OFLOXACIN [USP-RS]

Common Name

English

OFLOXACIN [USAN]

Common Name

English

HOE 280

Code

English

OCUFLOX

Brand Name

English

ofloxacin [INN]

Common Name

English

DL-8280

Code

English

OFLOXACIN [USP MONOGRAPH]

Common Name

English

OFLOXACIN [MI]

Common Name

English

NSC-727071

Code

English

Classification Tree Code System Code

WHO-ATC

J01MA01